Clinical study of niceritrol on serum lipids in the treatment of hyperlipidemia.

@article{Kibata1980ClinicalSO,
  title={Clinical study of niceritrol on serum lipids in the treatment of hyperlipidemia.},
  author={Masayoshi Kibata and Masayuki Ishida and Katsumi Asano and Hajime Uehara and Komei Saito and T Fuchimoto and K Ugaki and Hiroshi Murakami and Kiyokazu Matoba and Y Kotakemori and Kohji Shirai and Hitoshi Yoshioka and Masahiko Nanba and Muneaki Yasuda and Masao Ishizaki and Naoki Kitagawa and Koji Ikejiri and R Inohara and Burton J. Lee and S Saino and J Sakado and H Matuzaka and Katsuo Numata and Masayoshi Mandai and Keiko Miyake and Keijirou Nakamura},
  journal={Atherosclerosis},
  year={1980},
  volume={37 3},
  pages={333-42}
}
The effects of niceritrol, a nicotinic acid derivative, on the levels of HDL-cholesterol (HDL-Ch) and a mixture of VLDL- and LDL-Ch (VLDL- + LDL-Ch) were studied in hyperlipidemic patients. Serum total cholesterol (sTC) and serum triglyceride (sTG) were significantly reduced during niceritrol administration. Lipoprotein electrophoresis showed that niceritrol increased the alpha:beta ratio. HDL-Ch showed a significant increase of 12.5% by the 16th week of therapy. This increase was more marked… CONTINUE READING